Phase I study of epigenetic priming using azacitidine prior to neoadjuvant chemotherapy in patients with resectable esophageal and gastric adenocarcinoma.

Bryan J. Schneider,Manish A. Shah,Allyson J. Ocean,Elizabeta C. Popa,Andrew M. Schreiner,Paul J. Christos,Alice Mercado,Romae Palmer,Jeffrey L. Port,Nasser K. Altorki,Joseph M. Scandura

Phase I study of epigenetic priming using azacitidine prior to neoadjuvant chemotherapy in patients with resectable esophageal and gastric adenocarcinoma.

2014

Bryan J. Schneider
Manish A. Shah
Allyson J. Ocean
Elizabeta C. Popa
Andrew M. Schreiner
Paul J. Christos
Alice Mercado
Romae Palmer
Jeffrey L. Port
Nasser K. Altorki
Joseph M. Scandura

4047 Background: Epigenetic silencing of tumor suppressor genes (TSGs) is an acquired abnormality observed in cancer and is prototypically linked to DNA methylation. 5-Azacitidine (V) is a cytosine...

Keywords:

Pathology
Azacitidine
Priming (psychology)
Cancer research
Chemotherapy
Epigenetics
Medicine
Adenocarcinoma
Suppressor
Cancer
Gene
DNA methylation
Cytosine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations